  
Navin  Fluorine International Limited  602, 6th Floor, Natraj by Rustomjee, 194, M.V. Road & Western Express Highway, Near Kanakia 351 Building, Andheri (East), Mumbai 400069 India. T: +91 22 6650 9999    F: +91 22 6650 9800   E: info@nfil.in  W: www.nfil.in  CIN NO.: L24110MH1998PLC115499 
 
November 17, 2025 
  
BSE Limited 
Phiroze Jeejeebhoy Towers, 
Dalal Street, Fort, 
Mumbai 400001 
Scrip Code: 532504 
National Stock Exchange of India Limited 
Exchange Plaza,  
Bandra Kurla Complex, Bandra (East),  
Mumbai 400051 
Symbol: NAVINFLUOR  
  
Dear Sir/Madam, 
 
Subject: Intimation of Schedule of Analyst / Institutional Investor Meets  
 
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, 
we would like to inform you that the officials of Navin Fluorine International Limited (‘the Company’) 
will be interacting with Analysts / Investors on November 21, 2025. The details are as under: 
Date Conference detail Mode of 
Interaction Type of Interaction 
21.11.2025 JM Financial: Powering India’s Next 
Big Leap Physical One on One & Group 
Meeting 
 
Presentation to be made at the Meetings is enclosed. Discussions will be based on publicly available 
information. Kindly note that changes may happen due to exigencies on the part of Host / Company.   
 
This intimation is also being made available on the Company’s website at www.nfil.in 
 
Kindly take this intimation on record. 
 
Thanking you, 
For NAVIN FLUORINE INTERNATIONAL LIMITED 
 
 
Niraj B. Mankad 
President Legal and Company Secretary 
 
Investor Presentation - October 2025
Advancing With 
Purpose
2
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Navin Fluorine International Limited (the “Company”), have 
been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall 
not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by 
means of a statutory offering document containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or 
warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this 
Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents 
of, or any omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and 
collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, 
uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the 
economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its 
strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the 
Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could 
differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information 
contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and 
the Company is not responsible for such third party statements and projections.
Safe Harbor
Q2 & H1 FY26 Financial Performance
Q2FY26 - Performance at a glance 
Specialty CDMO
39%
 98%
Q2FY26
HPP
38%
Consolidated Financials
Sales
Rs.  758.4 Crs
+ 46% Y-o-Y
+ 5%  Q-o-Q
Operating EBITDA
Rs. 246.2 Crs
+ 129% Y-o-Y
+ 19% Q-o-Q 
Operating EBITDA Margin
32.5%
+ 1176 bps Y-o-Y
+ 395 bps Q-o-Q 
Revenue Growth (Y-o-Y)
Operating PBT
Rs. 179.3 Crs
+ 173% Y-o-Y
+ 27% Q-o-Q 
4
H1FY26 - Performance at a glance 
Specialty CDMO
37%
 57%
H1 FY26
HPP
41%
Consolidated Financials
Sales
Rs.  1483.8 Crs
+ 42% Y-o-Y
Operating EBITDA
Rs. 453.0 Crs
+ 118% Y-o-Y
Operating EBITDA Margin
30.5%
+ 1060 bps Y-o-Y
Revenue Growth (Y-o-Y)
Operating PBT
Rs. 320.5 Crs
+ 159% Y-o-Y
5
HFC MPP
Capex Announcements
6
Capex Details
Capex Rational
Amount & Completion Date
Peak Revenue Potential
Additional HFC capacity equivalent upto 15,000 MTPA of 
R32
Constructive global demand-supply environment driven by 
transition to low GWP gasses and increasing RAC and 
blends demand in India and export market
• Capex of Rs. 236.5 Crs to be funded by internal 
accruals.
• Project expected to be commissioned by Q3 FY27
~ Rs. 600-825 Crs per annum 
De-bottlenecking MPP capacity at Dahej to support 
launch of new molecule for a global innovator
• Strong projections received from global innovator to 
participate in their growth
• Purchase order received for CY26
• Capex of Rs. 75 Crs to be funded by internal accruals.
• Targeted  commissioning by Q3 FY27
~ Rs. 140-160  Crs per annum 
Business Vertical - HPP
7
Consolidated Financials
Q2FY26 HighlightsRevenues
Q2FY26
293
404
Q2 FY25 Q2 FY26
+38%
Revenue growth led by higher realizations and volumes in
both domestic and well as international markets
AHF capex : Mechanical trials underway, commissioning by 
Q3 FY26
✓ Capex for additional HFC capacity equivalent upto 15,000 
MTPA of R32
✓
For R32, both the plants are running at optimal capacity✓
✓
38%
62%
India International
Rs. crores
Business Vertical - Specialty Chemicals
8Consolidated Financials
Q2FY26 HighlightsRevenues
Q2FY26
158
220
Q2 FY25 Q2 FY26
+39%
Strong outlook for H2 backed by purchase orders
De-bottlenecking MPP capacity at Dahej to support launch 
of new molecule for a global innovator
✓
✓
✓
35%
65%
India International
Rs. crores
Chemours project is on track for completion in Q1FY27
Fluro specialty plant has started contributing meaningfully
from this quarter✓
Business Vertical - CDMO
9
Consolidated Financials
Q2FY26 HighlightsRevenues
Q2FY26
68
134
Q2 FY25 Q2 FY26
+98%
Order book pipeline till FY27 backed by purchase orders 
Strategy -in-action :
• EU Major – Supplies concluded for the material order in 
Q2 FY26 and in discussion for the future supplies
• Another EU Major – Scale up order received for supplies 
in Q3 & Q4 FY26
• Based on the successful deliveries of late-stage pipeline 
molecules, plant was audited by three global major 
innovators
✓
European CDMO MSA : 
• Validation batches started in cGMP4, supplies targeted by 
Jan 26 
• Strong outlook with 3 years projection
✓
✓
96%
4%
India International
Rs. crores
Consolidated Profitability Statement
10
Particulars (Rs. Crs) Q2 FY26 Q2 FY25 Y-o-Y 
Change % Q1 FY26 Q-o-Q 
Change % H1 FY26 H1 FY25 Y-o-Y 
Change %
Net Revenue From Operations 758.42 518.56 46.26% 725.40 4.55% 1,483.82 1,042.24 42.37%
Raw Material 312.90 223.98 307.71 620.61 454.37
Employee Expenses 73.04 76.95 77.57 150.61 155.14
Other Expenses 126.31 110.28 133.33 259.64 225.03
Operating EBITDA 246.17 107.35 129.32% 206.79 19.04% 452.96 207.70 118.08%
Operating EBITDA Margin 32.46% 20.70% 1,176 Bps 28.51% 395 Bps 30.53% 19.93% 1,060 Bps
Interest Expenses 30.30 13.86 30.35 60.65 29.46
Depreciation 36.58 27.90 35.24 71.82 54.61
Operating PBT 179.29 65.59 173.35% 141.20 26.98% 320.49 123.63 159.23%
Operating PBT Margin 23.64% 12.65% 1,099 Bps 19.47% 417 Bps 21.60% 11.86% 974 Bps
Other Income 18.21 11.16 13.91 32.12 21.42
Profit Before Tax 197.50 76.75 157.33% 155.11 27.33% 352.61 145.05 143.10%
Tax 49.13 17.93 37.94 87.07 35.03
Profit After Tax 148.37 58.82 152.24% 117.17 26.63% 265.54 110.02 141.36%
(Loss) From Associates And Joint Venture (Net) * 0.00 (0.01) (0.01) 0.00
Other Comprehensive Income
Items That Will Not Be Reclassified To Profit & Loss (Net Of Tax) (1.26) (0.16) (1.27) (2.53) 0.38
Items that may be reclassified to profit and loss 0.65 1.74 1.71 2.36 1.83
Total Comprehensive Income For The Period 147.76 60.40 144.64% 117.60 25.65% 265.36 112.23 136.44%
*Amounts are below rounding off norms adopted by the Group 
Consolidated Balance Sheet Statement
11
Particulars (Rs. Crs) Sep’25 Mar’25
ASSETS
Non-Current  Assets
Property, plant and equipment 2,579.33 2,550.47 
Right-of-use assets 53.14 46.27 
Capital work-in-progress 549.85 349.79 
Investment properties 48.81 49.38 
Goodwill 87.76 87.76 
Other intangible assets 10.65 2.41 
Other intangible assets under development -   5.63 
Financial assets
(i) Investment accounted for using the equity method 0.71 0.72 
(ii) Investments 5.58 7.40 
(iii) Loans 0.14 0.18 
(iv) Other financial assets 73.06 22.39 
Non current-tax assets (net) 6.76 12.98 
Other non- current assets 117.32 106.16 
Total Non- Current Assets 3,533.11 3,241.55
Current Assets
Inventories 357.95 322.42 
Financial assets
(i) Investments 791.95 471.80 
(ii) Trade receivables 699.46 582.42 
(iii) Cash and cash equivalents 49.18 19.68 
(iv) Bank Balance other than (iii) above 22.97 20.84 
(v) Loans 0.11 0.09 
(vi) Other financial assets 28.41 18.79 
Other current assets 159.47 152.80 
Total Current Assets 2,109.50 1,588.84 
TOTAL ASSETS 5,642.61 4,830.38 
Particulars (Rs. Crs) Sep’25 Mar’25
EQUITY
(a) Equity share capital 10.25 9.92 
(b) Other equity
(i) Reserves & Surplus 3,430.53 2,458.38 
(ii) Other reserves 160.29 157.93 
Total Equity 3,601.07 2,626.23 
LIABILITIES
Non ‐ Current Liabilities
Financial liabilities
(i)Borrowings 948.95 1,053.44 
(ii) Lease liabilities 22.04 13.19 
Provisions 22.66 20.42 
Deferred tax liabilities (net) 87.52 75.41 
Other non- current liabilities 74.14 13.44 
Contract liabilities 118.56 113.59
Total Non ‐ Current Liabilities 1,273.87 1,289.49 
Current Liabilities
Financial liabilities
(i) Borrowings 194.85 387.29 
(ii) Lease liabilities 10.88 12.47 
(iii) Trade payables
(a) total outstanding dues of micro enterprises and small enterprises 28.93 44.68 
(b) total outstanding dues of creditors other than micro enterprises and 
small enterprises 362.90 282.28 
(iv) Other financial liabilities 80.93 99.15 
Contract liabilities 25.87 26.23 
Provisions 10.00 6.46 
Current tax liabilities (net) 6.06 3.94 
Other current liabilities 47.25 52.16 
Total Current Liabilities 767.67 914.66 
Total Liabilities 2,041.54 2,204.15
TOTAL EQUITY AND LIABILITIES 5,642.61 4,830.38
Consolidated Cash Flow Statement
12
Cash Flow Statement (Rs. Crs.) H1 FY26 H1 FY25
Cash Flow from Operating Activities
Profit before Tax 352.61 145.05 
Adjustment for Non-Operating Items 102.75 78.07 
Operating Profit before Working Capital Changes 455.36 223.12 
Changes in Working Capital (108.69) 29.49 
Cash Generated from Operations 346.67 252.61 
Less: Direct Taxes paid (65.79) (38.74)
Net Cash from Operating Activities 280.88 213.87 
Cash Flow from Investing Activities (594.32) (160.39)
Cash Flow from Financing Activities 342.94 (51.08)
Net increase/ (decrease) in Cash & Cash equivalent 29.50 2.40 
Add: Cash and cash equivalents as at 1st April 19.68 6.64 
Add: Net effect of exchange gain on cash and cash equivalents -   -   
Cash and cash equivalents as at 30th September 49.18 9.04 
Standalone Profitability Statement
13
Particulars (Rs. Crs.) Q2 FY26 Q2 FY25 Y-o-Y 
Change % Q1 FY26 Q-o-Q 
Change % H1 FY26 H1 FY25 Y-o-Y 
Change %
Net Revenue From Operations 562.37 385.82 45.76% 542.95 3.58% 1,105.32 762.10 45.04%
Raw Material 251.08 174.89 239.44 490.52 346.02
Employee Expenses 52.61 55.95 54.61 107.22 113.14
Other Expenses 93.74 83.24 94.70 188.44 167.77
Operating EBITDA 164.94 71.73 129.95% 154.20 6.96% 319.14 135.16 136.12%
Operating EBITDA Margin 29.33% 18.59% 1,074 Bps 28.40% 93 Bps 28.87% 17.74% 1,114 Bps
Interest Expenses 2.08 1.29 0.84 2.92 1.98
Depreciation 19.76 17.10 18.80 38.56 33.67
Operating PBT 143.10 53.33 168.31% 134.56 6.35% 277.66 99.50 179.05%
Operating PBT Margin 25.45% 13.82% 1,162 Bps 24.78% 66 Bps 25.12% 13.06% 1,206 Bps
Other Income 33.45 12.46 14.87 48.32 32.51
Profit Before Tax 176.55 65.80 168.33% 149.43 18.15% 325.98 132.03 146.90%
Tax 42.54 15.76 36.67 79.21 31.96
Profit After Tax 134.01 50.04 167.83% 112.76 18.84% 246.77 100.07 146.61%
Other Comprehensive Income
Items That Will Not Be Reclassified To Profit & Loss (Net Of Tax) (1.27) (0.19) (1.08) (2.35) 0.31
Total Comprehensive Income For The Period 132.74 49.86 166.24% 111.68 18.86% 244.42 100.38 143.49%
Standalone Balance Sheet Statement
14
Particulars (Rs. Crs.) Sep’25 Mar’25
ASSETS
Non-Current  Assets
Property, plant and equipment 725.48 721.09 
Right-of-use assets 29.67 22.03 
Capital work-in-progress 116.23 48.58 
Other intangible assets 9.98 1.48 
Intangible assets under development - 5.63
Investment properties 37.69 38.12 
Financial assets
Investment in Subsidiaries and Joint Ventures 1,143.69 943.69 
Investments 5.58 7.40 
Loans 0.14 0.18 
Other financial assets 18.22 17.26 
Non current-tax assets (net) 5.59 12.00 
Other non- current assets 5.29 2.09 
Total Non- Current Assets 2,097.56 1,819.55 
Current Assets
Inventories 184.30 168.79 
Financial Assets
(i) Investments 788.66 468.70 
(ii) Trade receivables 515.36 442.28 
(iii) Cash and Cash Equivalents 30.88 3.06 
(iv) Bank Balance other than (iii) above 3.50 3.90 
(v) Loans 270.39 18.10 
(vi) Other financial assets 10.50 8.06 
Other current assets 59.00 34.26 
Total Current Assets 1,862.59 1,147.15
TOTAL ASSETS 3,960.15 2,966.70 
Particulars (Rs. Crs) Sep’25 Mar’25
EQUITY
(a) Equity share capital 10.25 9.92 
(b) Other equity
(i) Reserves & Surplus 3,290.00 2,336.41 
(ii) Other reserves 151.05 151.05 
Total Equity 3,451.30 2,497.38 
LIABILITIES
Non ‐ Current Liabilities
Financial liabilities
(i)Borrowings - -
(ii) Lease liabilities 20.95 11.56 
(iii) Provisions 16.26 15.34 
(iv) Deferred tax liabilities (net) 44.94 39.92 
(v) Other non- current liabilities 13.43 13.44 
Total Non ‐ Current Liabilities 95.58 80.26 
Current Liabilities
Financial liabilities
Borrowings 18.49 34.96 
(ii) Lease liabilities 9.80 11.40 
(iii) Trade payables
(a) total outstanding dues of micro enterprises and small 
enterprises 28.39 21.47 
(b) total outstanding dues of creditors other than micro enterprises 
and small enterprises 288.15 247.84 
(iv) Other financial liabilities 27.84 28.66 
Contract liabilities 6.34 6.68 
Provisions 9.41 5.96 
Current tax liabilities (net) 5.57 3.66 
Other current liabilities 19.28 28.43 
Total Current Liabilities 413.27 389.06 
Total Liabilities 508.85 469.32
Total Equity and Liabilities 3,960.15 2,966.70
Standalone Cash Flow Statement
15
Cash Flow Statement (Rs. Crs.) H1 FY26 H1 FY25
Cash Flow from Operating Activities
Profit before Tax 325.98 132.03 
Adjustment for Non-Operating Items 0.41 20.20 
Operating Profit before Working Capital Changes 326.39 152.23 
Changes in Working Capital (75.34) (67.19)
Cash Generated from Operations 251.05 85.04 
Less: Direct Taxes paid (65.06) (38.23) 
Net Cash from Operating Activities 185.99 46.81 
Cash Flow from Investing Activities (839.81) (14.42) 
Cash Flow from Financing Activities 681.64 (32.08)
Net increase/ (decrease) in Cash & Cash equivalent 27.82 0.31 
Add: Cash and cash equivalents as at 1st April 3.06 1.69 
Add: Net effect of exchange gain on cash and cash equivalents -   -   
Cash and cash equivalents as at 30th September 30.88 2.00 
Company Overview
Resilient business model: 
diversified divisions, 
products, plants & end 
markets
17
Preferred source and a partner of choice for diverse fluorochemical solutions globally
Leveraging our fluorochemicals expertise, world-class manufacturing facilities, dynamic in-house R&D, advanced technologies and competent 
workforce, we have developed a comprehensive and diversified portfolio, encompassing:
Specialty Chemicals HPP CDMO
Geographies
Countries
Business Verticals
3
4
3
Factories
R&D Centres
Sales Offices
4
3
5
Total Customers
Total Employees
900+
1,498
As on March 31st  2025
3P approach to building 
capacities,  building scalable 
platforms and nurturing long-
term partnerships
18
3P 
FOCUS
Product
Platform
Partnerships
Diverse portfolio including fluorine-
based intermediates, specialty 
chemicals and inorganic chemicals
Focus on owning specific 
technologies and chemistries, that 
serve as building blocks (BB) for 
diverse business applications
We leverage these capabilities to 
diversify the product pipeline and 
strengthen our technology 
leadership
Partnerships
Forging multiyear partnerships to 
integrate within the global supply 
chain positioning alongside 
industry majors
Harnessing their expertise and 
resources to expand our reach and 
scale with impact
Trusted to deliver, where IP 
integrity meets excellence and 
performance
19
Strong partnership with Global 
Innovators across diverse 
segments
Robust R&D engagement supports 
co-development initiatives, 
accelerating innovation & 
customised solutions
Agile manufacturing 
infrastructure enabling rapid 
adaptation to shifting customer 
requirements and production 
scales
Swift absorption of new 
technology and replicating the 
same with precision at a 
commercial scale
Structured and disciplined 
project management ensures 
on-time and efficient project 
execution
Highly skilled and experienced 
large technology team enabling 
seamless product scale up at 
commercial scale
state-of-the-art Navin Research 
and Innovation Centre for the 
development and scale-up of 
complex and novel chemistries
Customer audits 
completed with major 
pharma innovations 
across the EU and US in 
FY25
32

20
One-Stop Fluorine provider, 
with the Group serving 
diverse customer needs, 
from gramscale to multi-
hundred-tonne quantities
Boosting capacity with 
ownership of one of 
India’s largest 
fluorination facilities
Modern manufacturing 
and Control Technologies 
drive process and 
product outcome
Prominent brand 
symbolising market 
leadership, service 
reliability, manufacturing 
excellence, superior 
price-value proposition 
and enduring trust
All units strategically 
located near multi-modal 
logistical options 
enhances connectivity 
with vendors and 
customers
Prioritising safety by 
managing hazardous 
chemicals like bromine 
and hydrofluoric acid, 
supported by an in-house 
process safety test lab
Rich experience, with 
decades of operational 
expertise, the Group is a 
pioneer in Indian 
Fluorine chemistry, 
establishing itself as a 
trusted supplier
Backward Integration of key 
products to basic feedstock 
through strategic, reliable, 
cost effective, offering a 
China-free alternative with 
minimal import dependency
Sustainable practices to 
drive environmental 
protection, water/energy 
conservation and 
workplace safety
Navin Fluorine: Precision in 
chemistry, purpose in 
execution

Strong R&D to manage diversified 
portfolios, from ideation to 
commercialization of molecules 
21
✓Focusses on developing and expanding 
fluorinated specialty chemicals beyond  
traditional verticals, extending our  
capabilities to participate in new-age 
emerging products.
✓The centre is home to 150+ chemists 
and 50+ engineers in technology and 
design (T&D) team who collectively work 
to develop a robust pipeline for HPP and 
Specialty businesses
Navin Research & Innovation 
Centre, Surat, Gujarat
✓Specialise in contract development and 
technology transfer of predominantly 
preclinical and clinical candidates by 
partnering with global pharmaceutical 
and biotech companies. 
✓The centre has 100+ team members, 
engaged in R&D, analytical and 
technology transfer, delivering timely 
end-to-end solutions, right from concept 
to commercial scale.
Navin Molecular R&D Centre, 
Madhya Pradesh and Manchester 
Driving research-based culture to develop 
complex KSMs for global pharma and biotech 
innovators
Backward integration into high end fluorine 
reagents bringing cost-effective KSM 
developments and enabling deeper relationships 
with global pharma and biotech innovators
Over five decades of experience in fluorine 
chemistry coupled with technology platforms 
allowing us to cater multi-step complex, value-
added products for our partners
Synergistic collaboration with customers and 
technology teams allows for timely and efficient 
delivery of commitments in an industry where 
time bound deliverables are key to success
Robust management commitment towards R&D 
investment based on emerging trends, leading to 
enhanced portfolioRs. 54.69 crores
KEY R&D HIGHLIGHTS FY25
Total R&D spend in FY25
Enhancing our agility, resilience 
and competitiveness to foster 
sustainable progress
22
Reputed Brand Mafron Rich Legacy
Integrated Fluorine
Provider
Diversified Portfolio Prominent ClienteleStrategic 
Partnerships
Committed to ESG
World-class
Infrastructure
Credible 
Certifications
Strong Global 
Presence
Thriving Workforce

Leading with ESG in Action
We undertook various environmentally friendly 
initiatives across our facilities in FY25
24
SURAT
• Reduction of 1,66,352 SCM of natural gas 
using waste heat from flue gas in the HF plant
• Steam condensate recovery across multiple 
plants saved 21,759 KL of DM water and 
3,93,138 SCM of natural gas 
• Reduced chiller compressor power 
consumption by 2,51,209 kWh and optimised 
steam usage in the BF₃ plant
• Achieved 1,287 KL DM water and effluent 
reduction in CDM and CAP processes
• Recovered 2,387 MT of CaF₂ from process 
sludge
DEWAS
• Increased solar electricity capacity from 1 MW 
to 2.2 MW in September 2024, enhancing 
renewable electricity usage
• Improved water recycling by utilising MEE 
condensate for utility purposes
• Only 0.3% of hazardous waste was sent to 
landfills
• Miyawaki concept adopted for plantation 
based around the ETP area, where 2,700 tree 
saplings various species are planted in 6,200 
sq. ft. area 
DAHEJ
• Condensate recovery from CPP, MEE, Orchid, 
Nektar and ETP RO recovery resulted in 45.4% 
water recycling rate
• Installed Variable Frequency Drive (VFD)
• Conversion of existing extraction cum 
condensing turbine into back pressure turbine 
initiated 
• Power optimisation by replacing existing 
cooling tower fans with energy-efficient fans
• Replaced LPG cylinder with natural gas for 
cooking canteen food 
Tree
Plantation 
Plastic Waste 
Management
Adoption of Renewable 
Electricity 
Progress and impact of our 
environmental initiatives
25
Progress On Environmental Targets 
 Dewas Plant is a Zero liquid discharge facility
20% Renewable 
electricity
1.58 crores kWh units 
Consumed renewable 
electricity across the 
operations 
2,51,209 kWh 
Reduction in electricity 
consumption of air 
compressor 
81% Total waste 
recycled 
15,539 GJ Total energy 
conserved 
7,93,606 KL Water 
recycled (60% of total 
water demand filled from 
recycled water)
All three sites of Navin Fluorine conferred with 8th 
Annual HSE Strategy Summit & Awards 2025 for 
'Commitment to Environmental Excellence
Greentech PCWR Excellence - 2024 Award for Pollution 
Control, Waste Management & Recycling
Dewas facility increased its renewable 
electricity share from 14.4% to 21.1% 
We have met with 100% compliance 
requirement for Plastic Waste 
Management under EPR Framework
Planted 14,429 trees across our facilities, 
that helped absorb 289 tCO₂e annually 
Source : Annual Report FY25
We are a Responsible Care 
Company
15
Board Committee
Highly 
engaged 
Board
actively involved in NFIL ’s 
strategic transformation
8
Board
Meetings 
during        
FY 2025
Board Demographics
5 Directors 
inducted since FY22
58 years median 
Directors’ age
Board Independence
7 of 9 Directors are 
Non-Executive
1 Woman Director 
(Independent) on the 
Board
5 of 9 
Directors are 
Independent
26
55% 
78% 
Highly Experienced  
Board to chair Committees
Audit Committee
Nomination & 
Remuneration 
Committee
Stakeholders’ 
Relationship 
Committee 
CSR Committee 
Risk Management Committee
55.5%
Fund Raising Committee
ESG Steering Committee

✓ Auditor qualification against the Company 
✓ Re-statements of  financial statements 
✓ Allegations of financial imprudence 
✓ Defaults for repayments, creditors and 
dividends  
Composition of the Statutory 
Committees as on March 31, 2025
Out of 4 Members of the Audit Committee, 3 
are Independent and 1 Non-Executive
27
Reported NO
 Out of 3 Members of Nomination and 
Remuneration Committee, 2 are 
Independent and 1 Non-Executive
Out of 3 Members of Stakeholders’ 
Relationship Committee, 2 are 
Independent and 1 Executive
Out of 6 Members of the Risk Management 
Committee, 1 is Independent, 2 are 
Executive, 1 is Non-Executive and 2 are Non-
Board Members
Structured policies and processes addressed 
investor grievances 
Accepted all the resolutions proposed by the 
Board to shareholders
Employed a rigorous Board evaluation policy; 
Board comprised eminent members 
Implemented an active succession 
pipeline for critical roles and the Board
Carried out an Internal audit  through an 
independent audit firm  reporting directly to the 
Audit Committee
Implemented two ESOP plans 
Out of 3 Members of the Corporate Social 
Responsibility Committee,  1 is 
Independent, 1 Executive and  1 Non-
Executive
Reflects the practices, regulations and 
protocols set by our board of directors
Diversity of thought and experience
28
Ms. Apurva S. Purohit (Independent Director)
She is a prominent Indian Business leader with over 32 years of experience in the media and 
entertainment industry. She has managed a diverse portfolio of businesses in partnership with 
private equity players and promoters, from early stage businesses to mature ones. She has a 
postgraduate diploma in management from IIM, Bangalore.
Mr. Vishad P. Mafatlal (Chairman)
He is an industrialist having varied experience of over 28+ Years in the field of Textiles and 
Chemicals. He holds a Bachelor of Science Degree in Economics from University of Pennsylvania, 
Wharton School.
Mr. Atul K. Srivastava (Independent Director)
He has an experience of over 48 years in large corporates, in the areas of Finance, Accounting, 
Taxation and Commerce. He is a Science Graduate and a Fellow Chartered Accountant - B. Sc (Hons), 
FCA.
Mr. Ashok U. Sinha (Independent Director)
He has a wealth of experience, competencies and expertise from his leadership journey at Bharat 
Petroleum Corporation Ltd. He has a BTech in Electrical Engineering from IIT, Kanpur, and a Post 
Graduate Diploma in Management from IIM, Bangalore, with specialisation in Finance.
Mr. Sunil S. Lalbhai (Non-Executive Non-Independent Director)
He is an industrialist having varied experience of over 35 years in chemicals and general 
management. He is a science graduate and holds M.S degree in chemistry from USA and also M.S 
degree in economic planning & policy from the Boston University of USA.
Mr. Sujal A. Shah (Independent Director)
He has an experience of over 32 years in the fields of Valuation, Due Diligence, Corporate 
Restructuring, Audit and Advisory. He is a commerce graduate and member of the Institute of 
Chartered Accountants of India.
Mr. Sudhir R. Deo (Non-Executive Non-Independent Director)
Mr. Deo has 45 years of association with Arvind Mafatlal Group (AMG), retired as Managing 
Director of NOCIL in July 2023. He has headed multiple mandates of the business including 
Manufacturing, Technology, Research, Strategy, Marketing and Supply Chain. He is an expert in 
ESG and Sustainability, focusing on implementation to elevate business value. He holds an M. Tech. 
in Chemical Engineering from IIT Kanpur.
Mr. Abhijit J. Joshi (Independent Director)
Mr. Joshi is the Founding and Managing Partner of Veritas Legal being regarded among Asia’s Top 
15 Private Wealth and M&A Lawyers with a legal career spanning 3 decades. Over the years, he has 
advised various business houses, promoter families, global conglomerates and large private equity 
houses across industry sectors on numerous complex deals and cases. He is a dual-qualified 
solicitor in India and England.
Mr. Nitin G. Kulkarni (Managing Director)
Mr. Kulkarni has over 3 decades of rich experience across the specialty chemicals value chain, 
specifically covering fluoro-chemicals and CDMO. He is a highly respected leader with a proven 
track record of: driving growth, establishing new business verticals, embedding manufacturing 
excellence, and execution of large projects, both brownfield and greenfield. He is also passionate 
about HSE and sustainability. He holds a Masters degree in Organic Chemistry from the University 
of Mumbai.
Investing in community
well-being
29
SHRI SADGURU SEVA
SANGH TRUST 
CHARUTAR AROGYA MANDAL 
BLIND PEOPLE’S
ASSOCIATION 
FOUNDATION FOR
PROMOTION OF SPORTS
SIR J.J. HOSPITAL
CONSUMER EDUCATION AND 
RESEARCH CENTRE 
ACT-EVE FOUNDATION
SHALA PRAVESHOTSAV
CANCER PATIENT AID 
ASSOCIATION
KC MAHINDRA
EDUCATION TRUST
SHAKTI FOUNDATION
MOBILE HEALTH VANS
CSR contribution made to:
Rs. 7.95 CroresTotal CSR expenditure for FY25

Track record of progressive dividends
30
65%
FY10
85%
65%
FY11
600%
65%
85%
FY12
75%
75%
FY13
85%
75%
FY14
85%
75%
FY15
110%
100%
FY16
75%
130%
110%
FY17
150%
180%
170%
FY18
200%
190%
FY19
150%
400%
FY20
300%
250%
FY21
300%
250%
FY22
350%
250%
FY23
150%
350%
250%
FY24
350%
250%
FY25
140% 150%
75%
150% 160% 160%
210%
315%
500%
390
750%
550% 550%
600%
750%
600%
FY26
325%
550%
Special Final Interim
22% 24% 37% 40% 36% 38% 29% 28% 33% 31% 30% 23% 20% 19% 32% 25%
* On standalone basis
Dividend as % of Face Value
Payout %*
For further information, please contact:
anish.ganatra@nfil.in
www.nfil.in
Navin Fluorine International Ltd.
CIN : L24110MH1998PLC115499
Mr. Anish Ganatra
Chief Financial Officer
anish.ganatra@nfil.in
www.nfil.in
Investor Relations Advisors:
payal.dave@in.mpms.mufg.com
MUFG Intime India Private Limited
A part of MUFG Corporate Markets, a division of MUFG Pension & 
Market Services
Ms. Payal Dave
payal.dave@in.mpms.mufg.com
LinkLink
LinkMeeting Request
pooja.swami@in.mpms.mufg.com
Ms. Pooja Swami
pooja.swami@in.mpms.mufg.com
